AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BioPharma Services Inc. Donates its Clinical Resources and Scientific Expertise in the Pursuit of Coronavirus COVID-19 Vaccine Research

March 2, 2020 GMT

TORONTO--(BUSINESS WIRE)--Mar 1, 2020--

With their state-of-the-art Phase 1 clinical infrastructure and expert team of scientific and medical personnel, BioPharma has today decided to donate its World Health Organization (WHO) approved facility for coronavirus COVID-19 vaccine research and treatments.

The global community continues to evolve and develop its response to large-scale health issues with organizations such as the Gates Foundation contributing to the development of infectious disease treatments. In the same way, the leaders at BioPharma wish to do their part for vaccine research to help control the growing epidemic of viruses and disease.

We invite all biotech companies working to create a vaccine for the developing global crisis of this novel coronavirus to contact us to discuss how BioPharma’s capabilities and resources can be mobilized to accelerate the development of therapeutic treatments and vaccines.

The BioPharma team has a strong history of philanthropy and has rallied in the past to respond to global medical needs. Dr. Fathi Abuzgaya MD, Chairman of the Board at BioPharma Services, has volunteered his time for medical missions to Libya and performed pro bono work in Canada as part of the University Health Network (UHN). In 2003, as Chief of Staff of Rouge Valley Health System in Toronto, Dr. Abuzgaya was instrumental in the response to the Severe Acute Respiratory (SARS) outbreak and later developing hospital policy for pandemic planning.

Dr. Abuzgaya, who is also a Principal Investigator remarked, “The race is on to shorten the development time of a COVID-19 vaccine. This coronavirus has not yet been categorized as a pandemic but based on what we have learned from SARS, the potential is real. The team here stands ready today to use our early stage medical research capabilities to support the development of a much needed vaccine.“

Renzo DiCarlo, CEO observed, “It truly is our people that differentiate BioPharma Services from other CROs. We are very proud today to offer our Phase I services to assist the global community. We have been an active partner with the USFDA to further drug research and we are well prepared to do the same for this current global need.”

About BioPharma Services Inc.
BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma has clinical facilities both in the USA and Canada with a total capacity of 300 beds with access to healthy volunteers and special populations. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200301005033/en/

CONTACT: Ms. Anna Taylor, Executive Vice President, Business Development, BioPharma Services, Inc.

ataylor@biopharmaservices.com

+1 (416) 716-9177Main Telephone: +1 (844) 747-8484

Email:info@biopharmaservices.com

Website:www.biopharmaservices.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: BioPharma Services Inc.

Copyright Business Wire 2020.

PUB: 03/01/2020 08:00 PM/DISC: 03/01/2020 08:00 PM

http://www.businesswire.com/news/home/20200301005033/en